natgillin/translations-raw huggingface dataset:
In placebo-controlled studies palpitations were reported >1% more often in the teriflunomide 7 mg group (but not in the teriflunomide 14 mg group) when compared to placebo.
V s placebom kontroliranih preskušanjih so o palpitacijah poročali > 1% pogosteje v skupini s teriflunomidom 7 mg (vendar ne v skupini s teriflunomidom 14 mg) v primerjavi s placebom.
In placebo-controlled studies the following was established: systolic blood pressure was >140 mm Hg in 19.9% of patients receiving 14 mg/day teriflunomide as compared to 15.5% receiving placebo; systolic blood pressure was >160 mm Hg in 3.8% of patients receiving 14 mg/day teriflunomide as compared to 2.0% receiving placebo; diastolic blood pressure was >90 mm Hg in 21.4% of patients receiving 14 mg/day teriflunomide as compared to 13.6% receiving placebo.
V s placebom kontroliranih študijah so ugotovili naslednje: sistolični krvni tlak je bil > 140 mm Hg pri 19,9 % bolnikov, ki so prejemali odmerek 14 mg teriflunomida na dan, in pri 15,5 % bolnikov, ki so prejemali placebo; sistolični krvni tlak je bil >160 mm Hg pri 3,8 % bolnikov, ki so prejemali odmerek 14 mg teriflunomida na dan, ter pri 2,0 % bolnikov, ki so prejemali placebo; diasistolični krvni tlak je bil > 90 mm Hg pri 21,4 % bolnikov, ki so prejemali odmerek 14 mg teriflunomida na dan, in pri 13,6 % bolnikov, ki so prejemali placebo.
In placebo-controlled studies with Kineret, treatment was associated with small reductions in the mean values for total white blood count and absolute neutrophil count (ANC).
V študijah z zdravilom Kineret, kontroliranih s placebom, je bilo zdravljenje povezano z majhnim znižanjem srednjih vrednosti vseh belih krvničk in absolutnega števila nevtrofilcev (ANC – „absolute neutrophil count“).
In placebo-controlled studies, bosentan-related decreases in haemoglobin concentration were not progressive, and stabilised after the first 4–12 weeks of treatment.
V študijah, nadziranih s placebom, z bosentanom povezana znižanja koncentracije hemoglobina niso napredovala in so se po prvih 4–12 tednih zdravljenja ustalila.
In placebo-controlled studies, elevations of hepatic transaminases were observed.
V s placebom kontroliranih študijah so opazili zvišanje jetrnih transaminaz.
In placebo-controlled studies, in total there have been 17 cases of peripheral neuropathy that were confirmed by nerve conduction studies, out of 898 patients treated.
V s placebom nadzorovanih preskušanjih je bilo v celoti 17 primerov periferne nevropatije, ki so bile potrjene s študijami živčnega prevajanja, od skupaj 898 zdravljenih bolnikov.
In placebo-controlled studies, macitentan-related decreases in haemoglobin concentration were not progressive, stabilised after the first 4–12 weeks of treatment and remained stable during chronic treatment.
V s placebom kontroliranih študijah z macitentanom povezano zmanjšanje koncentracij hemoglobina ni bilo progresivno in se je po prvih 4-12 tednih zdravljenja stabiliziralo, nato pa je ostalo med kroničnim zdravljenjem stabilno.
In placebo-controlled studies, the incidence of proteinuria was higher in patients treated with Tecfidera (9%) compared to placebo (7%).
V s placebom kontroliranih študijah je bila incidenca proteinurije višja pri bolnikih, zdravljenih z zdravilom Tecfidera (9 %), v primerjavi s placebom (7 %).
In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2 %) and the placebo groups (56.5 %).
V s placebom kontroliranih preskušanjih z bolniki s hipertenzijo, se celotna pogostost neželenih dogodkov med skupinama z irbesartanom (56,2 %) in placebom (56,5 %) ni razlikovala.
In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life threatening, or requiring hospitalisation or intravenous antibiotics) was observed.
V preskušanjih, nadzorovanih s placebom, niso opazili zvečanja incidence resnih okužb (s smrtnim izidom, življenjsko ogrožajočih okužb ali takih, ki so zahtevale hospitalizacijo ali intravenske antibiotike).
In plasma, both brinzolamide and N- desethylbrinzolamide concentrations are low and generally below assay quantitation limits (<7.5 ng/ml).
V plazmi sta tako koncentraciji brinzolamida kot N-desetilbrinzolamida nizki in običajno pod mejo kvantifikacije (<7,5 ng/ml).
In plasma, FXIII circulates as a heterotetramer [A2B2] composed of 2 FXIII A-subunits and 2 FXIII B- subunits held together by strong non-covalent interactions.
V plazmi FXIII kroži kot heterotetramer [A2B2], sestavljen iz 2 podenot A in 2 podenot B FXIII, povezanih z močnimi nekovalentnimi vezmi.
In plasma, olanzapine is bound to albumin and α1-acid glycoprotein.
V plazmi se olanzapin veže predvsem na albumin in 1-kisli glikoprotein.
In plasma, tacrolimus is highly bound (> 98.8%) to plasma proteins, mainly to serum albumin and α-1-acid glycoprotein.
V plazmi je takrolimus v veliki meri (> 98,8 %) vezan na plazemske beljakovine, predvsem na serumski albumin in α-1-kisli glikoprotein.
In plasma, tacrolimus is highly bound (>98.8%) to plasma proteins, mainly to serum albumin and α-1-acid glycoprotein.
V plazmi je takrolimus v veliki meri (> 98,8 %) vezan na plazemske beljakovine, predvsem na serumski albumin in α-1-kisli glikoprotein.
In plasma, the principal circulating compound is the metabolite M1.
Glavna spojina v plazmi je presnovek M1.
In plasma, the relative exposures of the S- and R- enantiomers of lenalidomide are approximately 56% and 44%, respectively.
V plazmi je relativna izpostavitev S-enantiomera lenalidomida približno 56-odstotna in R- enantiomera približno 44-odstotna.
In plasma, unchanged thalidomide represents 80% of the circulatory components.
V plazmi nespremenjeni talidomid predstavlja 80 % sestavin v krvnem obtoku.
In plastic box: Lyophilisate: vial (glass) and Solvent: vial (glass)
Liofilizat: viala (steklena) Topilo: viala (steklena)
In PNH patients, pharmacodynamic activity correlates directly with eculizumab serum concentrations and maintenance of trough levels above  35 microgram/ml results in essentially complete blockade of haemolytic activity in the majority of PNH patients.
Med farmakodinamično aktivnostjo in koncentracijami ekulizumaba v serumu pri bolnikih s PNH obstaja neposredna korelacija; vzdrževanje minimalne koncentracije nad  35 mikrogramov/ml pri večini bolnikov s PNH povzroči praktično popolno zaustavitev hemolize.
In PNH patients, uncontrolled terminal complement activation and the resulting complement- mediated intravascular haemolysis are blocked with Soliris treatment.
Pri bolnikih s PNH sta zaradi zdravljenja z zdravilom Soliris zavrta nekontrolirana aktivacija terminalnega komplementa in posledična intravaskularna hemoliza, ki je posredovana s komplementom.
In PNH, chronic administration of Soliris resulted in a rapid and sustained reduction in complement- mediated haemolytic activity.
Pri PNH je kronična uporaba zdravila Soliris povzročila hitro in trajno zmanjšanje hemolize, pogojene s komplementom.
In PNH, treatment for patients aged 18 and over consists of an infusion (drip into a vein) of 600 mg over 25 to 45 minutes once a week, followed by 900 mg in the fifth week.
Pri paroksizmalni nočni hemoglobinuriji se zdravljenje pri bolnikih, starejših od 18 let, izvaja v obliki infundiranja (kapalne infuzije v veno) 600-miligramskega odmerka v trajanju 25 do 45 minut enkrat tedensko, čemur sledi infundiranje 900-miligramskega odmerka v petem tednu.
In polyarticular juvenile idiopathic arthritis, around 40% of patients aged between 4 and 17 years receiving Humira, either alone or in combination with methotrexate, had a flare-up of arthritis, compared with around 69% of those receiving placebo.
Pri poliartikularnem juvenilnem idiopatskem artritisu je artritis ponovno izbruhnil pri približno 40 % bolnikov, starih od štiri do 17 let, ki so prejemali zdravilo Humira bodisi kot samostojno zdravilo bodisi v kombinaciji z metotreksatom, v primerjavi z 69 % tistih, ki so prejemali placebo.
In polyarticular juvenile idiopathic arthritis, it took longer for the disease to flare up in the patients continuing to receive Orencia than those who switched to placebo.
Pri poliartikularnem juvenilnem idiopatskem artritisu je kasneje prišlo do novega izbruha bolezni pri bolnikih, ki so še naprej jemali zdravilo Orencia, kot pri tistih, ki so prešli na jemanje placeba.
In polyarticular juvenile idiopathic arthritis, Orencia infusion has been studied in one main study involving patients aged between six and 17 years whose previous treatment had failed.
Pri poliartikularnem juvenilnem idiopatskem artritisu so zdravilo Orencia proučevali v eni glavni študiji, ki je zajemala bolnike, stare do šest do 17 let, pri katerih predhodno zdravljenje ni bilo uspešno.
In Pom + LD- Dex treated patients infections led to dose discontinuation in 2.0% of patients, to treatment interruption in 14.3% of patients, and to a dose reduction in 1.3% of patients.
V skupini Pom + NO-deks je okužba povzročila ukinitev odmerjanja pri 2,0 % bolnikov, prekinitev zdravljenja pri 14,3 % bolnikov in zmanjšanje odmerka pri 1,3 % bolnikov.
In Pom + LD-Dex treated patients neutropenia was infrequently serious (2.0% of patients), did not lead to treatment discontinuation, and was associated with treatment interruption in 21.0% of patients, and with dose reduction in 7.7% of patients.
Pri bolnikih, zdravljenih s Pom + NO-deks, je bila nevtropenija redko resna (2,0 % bolnikov), ni povzročila ukinitve zdravljenja in je bila povezana s prekinitvijo zdravljenja pri 21,0 % bolnikov in z zmanjšanjem odmerka pri 7,7 % bolnikov.
In Pom + LD-Dex treated patients, thrombocytopenia was serious in 1.7% of patients, led to dose reduction in 6.3% of patients, to dose interruption in 8% of patients and to treatment discontinuation in 0.7% of patients. (see sections 4.2 and 4.4)
Pri bolnikih, zdravljenih s Pom + NO-deks, je bila trombocitopenija resna pri 1,7 % bolnikov, zmanjšanje odmerka je povzročila pri 6,3 % bolnikov, prekinitev odmerjanja pri 8 % bolnikov in ukinitev zdravljenja pri 0,7 % bolnikov (glejte poglavji 4.2 in 4.4).
In Pom + LD-Dex treated patients, VTE was reported as serious in 1.7% of patients, no fatal reactions were reported in clinical studies, and VTE was not associated with dose discontinuation.
Pri bolnikih, zdravljenih s Pom + NO-deks, so o resnih VTE poročali pri 1,7 % bolnikov, pri čemer v kliničnih študijah o smrtnih primerih niso poročali, VTE pa niso bili povezani z ukinitvijo odmerjanja.
In PONV, the usual dose is one 40 mg capsule given to adults within the three hours before the patient is anaesthetised (‘put to sleep’).
Pri postoperativni slabosti in bruhanju je običajni odmerek za odrasle 40-miligramska kapsula, ki jo bolnik prejme tri ure pred anestezijo („preden ga uspavajo“).
In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, arterial embolic and thrombotic events were reported in 2.8% of patients receiving axitinib.
V zbranih kliničnih študijah z aksitinibom (n = 672) pri zdravljenju bolnikov z RCC so o arterijskih emboličnih in trombotičnih dogodkih poročali pri 2,8 % bolnikov, ki so prejemali aksitinib.
In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, gastrointestinal perforation and fistula were reported in 1.9% of patients receiving axitinib.
V zbranih kliničnih študijah z aksitinibom (n = 672) pri zdravljenju bolnikov z RCC so o perforaciji prebavil in fistuli poročali pri 1,9 % bolnikov, ki so prejemali aksitinib.
In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, haemorrhagic events were reported in 25.7% of patients receiving axitinib.
V zbranih kliničnih študijah z aksitinibom (n = 672) pri zdravljenju bolnikov z RCC so o hemoragičnih dogodkih poročali pri 25,7 % bolnikov, ki so prejemali aksitinib.
In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, hypothyroidism was reported in 24.6% of patients receiving axitinib.
V zbranih kliničnih študijah z aksitinibom (n = 672) pri zdravljenju bolnikov z RCC so o hipotiroidizmu poročali pri 24,6 % bolnikov, ki so prejemali aksitinib.
In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, polycythaemia was reported in 1.5% of patients receiving axitinib.
V zbranih kliničnih študijah z aksitinibom (n = 672) pri zdravljenju bolnikov z RCC so o policitemiji poročali pri 1,5 % bolnikov, ki so prejemali aksitinib.
In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, venous embolic and thrombotic events were reported in 2.8% of patients receiving axitinib.
V zbranih kliničnih študijah z aksitinibom (n = 672) pri zdravljenju bolnikov z RCC so o venskih emboličnih in trombotičnih dogodkih poročali pri 2,8 % bolnikov, ki so prejemali aksitinib.
In pooled controlled studies using an every 2 week dosing interval, 796 of 3340 patients (23.8%) treated with Praluent had two consecutive values of LDL-C <25 mg/dL (<0.65 mmol/L), including 288 patients (8.6%) with two consecutive values <15 mg/dL (<0.39 mmol/L).
Kumulativno je imelo v kontroliranih študijah, kjer je bil uporabljen odmerni interval na 2 tedna, 796 od 3340 bolnikov (23,8 %), ki so dobivali zdravilo Praluent, dve zaporedni vrednosti LDL-H < 25 mg/dl (< 0,65 mmol/l) med njimi je 288 bolnikov (8,6 %) imelo dve zaporedni vrednosti < 15 mg/dl (< 0,39 mmol/l).
In pooled data from the major efficacy trials, the proportion of patients experiencing successful penetration on vardenafil were as follows: psychogenic erectile dysfunction (77-87%), mixed erectile dysfunction (69-83%), organic erectile dysfunction (64-75%), elderly (52-75%), ischaemic heart disease (70-73%), hyperlipidemia (62-73%), chronic pulmonary disease (74-78%), depression (59-69%), and patients concomitantly treated with antihypertensives (62-73%).
Na podlagi podatkov, zbranih iz najpomembnejših študij učinkovitosti, je bila penetracija po zaužitju vardenafila uspešna pri bolnikih s psihogeno erektilno disfunkcijo (77 do 87 %), mešano erektilno disfunkcijo (69 do 83 %), organsko erektilno disfunkcijo (64 do 75 %), pri starejših bolnikih (52 do 75 %), bolnikih z ishemično boleznijo srca (70 do 73 %), s hiperlipidemijo (62 do 73 %), kronično pljučno boleznijo (74 do 78 %), depresijo (59 do 69 %) ter pri bolnikih, ki so se sočasno zdravili z antihipertenzivi (62 do 73 %).
In pooled data from three trials, 39 patients with relapsed or chemoresistant, bulky disease (single lesion  10 cm in diameter), low grade or follicular B cell NHL received 375 mg/m2 of MabThera as intravenous infusion weekly for four doses.
Združeni podatki treh preskušanj navajajo, da je 39 bolnikov, pri katerih se je nizko maligni ali folikularni B-celični ne-Hodgkinov limfom ponovil ali pa so bili bolniki neodzivni na kemoterapijo in so imeli obsežno bolezen (ena lezija  10 cm v premeru), prejelo 4 odmerke po 375 mg/m2 zdravila MabThera v obliki intravenske infuzije enkrat na teden.
In poorly interferon responsive patients (defined as < 1-log10 decline in HCV-RNA at TW 4) the use of triple therapy should be considered on a case by case basis, as the likelihood of achieving sustained virologic response (SVR) with triple therapy is lower in these patients (see section 5.1).
Pri bolnikih, slabo odzivnih na interferon (opredeljenih kot tisti, ki so imeli 4. teden zdravljenja < 1-log10 zmanjšanje HCV-RNA), je treba o zdravljenju s tremi zdravili razmisliti pri vsakem posameznem bolniku, ker je verjetnost za dosego trajnega virološkega odziva (SVR – Sustained Virologic Response) s tremi zdravili pri teh bolnikih manjša (glejte poglavje 5.1).
In post hoc analyses of individuals (who received at least one vaccination) with evidence of a prior infection with a vaccine HPV type (seropositive) no longer detectable (PCR negative) at vaccination onset, the efficacy of Gardasil to prevent conditions due to the recurrence of the same HPV type was 100% (95% CI: 62.8, 100.0; 0 vs.
V post hoc analizah posameznikov (ki so bili cepljeni vsaj enkrat) s potrjeno predhodno okužbo s tipom HPV, ki ga vsebuje cepivo (seropozitivni) in ki se ga ob začetku cepljenja ni dalo več določiti (PCR negativni), je bila učinkovitost cepiva Gardasil pri preprečitvi stanj zaradi ponovne prisotnosti istega tipa HPV 100 % (95-odstotni IZ: 62,8; 100,0; 0 oz.
In post hoc analyses of individuals (who received at least one vaccination) with evidence of a prior infection with a vaccine HPV type (seropositive) no longer detectable (PCR negative) at vaccination onset, the efficacy of Silgard to prevent conditions due to the recurrence of the same HPV type was 100% (95% CI: 62.8, 100.0; 0 vs.
V post hoc analizah posameznikov (ki so bili cepljeni vsaj enkrat) s potrjeno predhodno okužbo s tipom HPV, ki ga vsebuje cepivo (seropozitivni) in ki se ga ob začetku cepljenja ni dalo več določiti (PCR negativni), je bila učinkovitost cepiva Silgard pri preprečitvi stanj zaradi ponovne prisotnosti istega tipa HPV 100 % (95-odstotni IZ: 62,8; 100,0; 0 oz.
In post marketing experience these events have been reported in patients treated with memantine.
Po začetku trženja zdravila so te dogodke navajali pri bolnikih, zdravljenih z memantinom.
In post marketing experience these symptoms have also been observed in Parkinson's disease patients treated with AZILECT.
V post-marketinških izkušnjah so prav tako zaznali navedene simptome pri bolnikih s Parkinsonovo boleznijo, ki so bili zdravljeni z zdravilom AZILECT.
In post marketing experience these symptoms have also been observed in Parkinson's disease patients treated with Rasagiline ratiopharm.
V post-marketinških izkušnjah so prav tako zaznali navedene simptome pri bolnikih s Parkinsonovo boleznijo, ki so bili zdravljeni z zdravilom Razagilin ratiopharm.
In post marketing experience, a differentiation syndrome, like retinoic acid syndrome, has also been reported for the treatment of malignancies other than APL with TRISENOX.
Po začetku trženja so poročali o pancitopeniji; z uporabo zdravila TRISENOX za zdravljenje drugih malignosti kot APL so poročali o sindromu diferenciacije kot je sindrom retinojske kisline.
In post marketing experience, serious, life-threatening, and sometimes fatal cases of encephalitis and meningitis caused by herpes simplex or varicella zoster have been reported in multiple sclerosis patients receiving TYSABRI.
V izkušnjah v obdobju po začetku trženja so pri bolnikih z multiplo sklerozo, zdravljenih z zdravilom TYSABRI, poročali o resnih, življenjsko nevarnih in včasih smrtnih primerih encefalitisa in meningitisa, ki ju povzročajo virusi herpes simplex ali virusi varicella zoster.
In post marketing experience, these symptoms have also been observed in Parkinson's disease patients treated with rasagiline.
V post-marketinških izkušnjah so prav tako zaznali navedene simptome pri bolnikih s Parkinsonovo boleznijo, ki so bili zdravljeni z razagilinom.
In post marketing period, there was one case of elevated blood pressure in a patient using the ophthalmic vasoconstrictor tetrahydrozoline hydrochloride while taking rasagiline.
V obdobju trženja je prišlo do enega primera zvišanega krvnega tlaka pri bolniku, ki je med jemanjem razagilina uporabljal očesni vazokonstriktor tetrahidrozolin.
In post- marketing experience of linagliptin there have been spontaneously reported adverse reactions of acute pancreatitis.
V spontanih poročilih po začetku trženja linagliptina so poročali o neželenih učinkih akutnega pankreatitisa.
In post- marketing experience there have been cases of worsening or recurrence of atrial fibrillation after administration of Rapiscan.
V obdobju trženja zdravila so bili primeri poslabšanja ali ponovitve atrijske fibrilacije po dajanju zdravila Rapiscan.
In post- marketing experience these events have been reported in patients treated with Axura.
V okviru postmarketinških izkušenj so te dogodke navajali pri bolnikih, zdravljenih z zdravilom Axura.
In post- marketing experience these events have been reported in patients treated with Memantine Merz.
V okviru postmarketinških izkušenj so te dogodke navajali pri bolnikih, zdravljenih z zdravilom Memantine Merz.
In post- marketing experience these events have been reported in patients treated with memantine.
Pri bolnikih, zdravljenih z memantinom, so o teh dogodkih poročali v obdobju trženja zdravila.
In post- marketing experience these events have been reported in patients treated with memantine.
V okviru postmarketinških izkušenj so te dogodke navajali pri bolnikih, zdravljenih z memantinom.
In post- marketing experience these reactions have been reported in patients treated with Ebixa.
V okviru izkušenj v obdobju trženja so te učinke navajali pri bolnikih, zdravljenih z zdravilom Ebixa.
In post-marketing data, 305 cases of dizziness were reported.
V obdobju trţenja zdravila so poročali o 305 primerih vrtoglavice.
In post-marketing experience
Izkušnje v obdobju trženja zdravila
In post-marketing experience isolated cases with international normalized ratio (INR) increases have been reported in patients concomitantly treated with warfarin.
V okviru postmarketinških izkušenj so poročali o osamljenih primerih povečanja mednarodno umerjenega razmerja (INR) pri bolnikih, ki so bili sočasno zdravljeni z varfarinom.
In post-marketing experience of greater than 5,000 patients treated, this incidence is approximately 19% (see section 4.2).
V izkušnjah iz obdobja trženja z več kot 5.000 zdravljenimi bolniki je bila ta incidenca približno 19 % (glejte poglavje 4.2).
In post-marketing experience of greater than 5,000 patients treated, this incidence is approximately 19% (see section 4.4).
V izkušnjah iz obdobja trženja z več kot 5.000 zdravljenimi bolniki je bila ta incidenca približno 19 % (glejte poglavje 4.4).
In post-marketing experience very rare cases of atrial flutter with 1:1 atrioventricular conduction are observed.
V obdobju po začetku trženja zdravila so v zelo redkih primerih opazili atrijsko undulacijo z atrioventrikularnim prevajanjem 1:1.
In post-marketing experience with Ferriprox, neurological disorders (such as tremors, walking disorders, double vision, involuntary muscle contractions, problems with movement coordination) have been reported in children who had been voluntarily prescribed more than double the maximum recommended dose of 100 mg/kg/day for several years.
V obdobju trženja zdravila Ferriprox so poročali o nevroloških motnjah (kot so tremor, motnje pri hoji, dvojni vid, neželeno krčenje mišic in težave s koordinacijo gibanja) pri otrocih, ki so prostovoljno nekaj let prejemali več kot dvakraten največji priporočeni odmerek 100 mg/kg/dan.
In post-marketing experience, anaphylaxis (including anaphylactic shock and generalised rash) has been reported very rarely following administration of Samsca.
V izkušnjah iz obdobja trženja so zelo redko po uporabi zdravila Samsca poročali o anafilaksi (vključno z anafilaktičnim šokom in generaliziranim izpuščajem).
In post-marketing experience, cases of anaphylactic-like reactions, including laryngeal/pharyngeal oedema and severe bronchospasm, and seizure have been associated with infliximab administration.
V okviru izkušenj v obdobju trženja je bila uporaba infliksimaba povezana s primeri anafilaktoidnih reakcij, vključno z edemom grla ali žrela, in s hudim bronhospazmom ter epileptičnimi napadi.
In post-marketing experience, cases of angioedema or angioedema-like reactions have been reported when aliskiren was co-administered with ACEIs and/or ARBs.
Med izkušnjami v obdobju trženja zdravilaso o angioedemu oziroma angioedemu podobnih reakcijah poročali v primerih sočasne uporabe aliskirena z zaviralci angiotenzinske konvertaze in/ali z zaviralci angiotenzinskih receptorjev.
In post-marketing experience, FVIII inhibitor development has been observed.
V obdobju trženja so opazili razvoj zaviralca faktorja VIII.
In post-marketing experience, isolated cases with international normalized ratio (INR) increases have been reported in patients concomitantly treated with warfarin.
V okviru izkušenj iz obdobja trženja so pri bolnikih, ki so bili sočasno zdravljenji z varfarinom, poročali o posameznih primerih povečanja mednarodnega umerjenega razmerja (INR).